China's Pharmaceutical Industry Surges as New Economic Growth Engine with Revenue Projected to Hit US$2.1 Trillion by 2030
Wednesday, January 21, 2026
China's pharmaceutical industry has emerged as a pivotal engine of economic growth, propelled by surging demand from an ageing population and aggressive global expansion strategies. According to recent estimates from UBS, the country's drug and medical device businesses are projected to exceed US$2.1 trillion in revenue by 2030, escalating further to US$3.2 trillion annually by 2050. This remarkable trajectory builds on 2024 sales of approximately US$1.4 trillion, representing a 50% increase over the next six years.
The primary catalyst is China's rapidly ageing demographics, which is boosting per-capita medical spending and creating unprecedented opportunities for pharmaceutical firms. Chen Chen, head of China healthcare research at UBS, highlights that innovative drugs—novel medicines addressing unmet needs, including new chemical entities and advanced biologics—will lead this growth with an annualized rate of 20% from 2026 to 2030. This momentum is expected to moderate to 8.8% between 2030 and 2040 as the market matures.
Leading Chinese biotech companies are at the forefront of this transformation. Shanghai Henlius Biotech, a spin-off from Fosun Pharmaceutical founded in 2010, exemplifies the sector's evolution from biosimilars to innovative international players. CEO Zhu Jun notes that Henlius now supplies 10 drugs to 60 global markets, benefiting 95 million patients, with plans to double its portfolio to over 20 by 2030. The company's integrated system spans research and development, drug registration, manufacturing, and a mature global clinical and commercialization network, enabling sustained overseas growth. Products have gained approvals in Europe and the US, showcasing China's capability in engineering comprehensive global strategies.
Biosimilars, officially approved versions of originator products post-patent expiry, have served as a foundational stepping stone. Henlius focuses on oncology, autoimmune diseases, and invests heavily in cutting-edge areas like antibody-drug conjugates, multispecific antibodies, and trichloroethylene drugs to bolster international presence. In the first half of 2025, the Hong Kong-listed firm reported a net profit of 390 million yuan (US$56 million), stable from the prior year, with revenue up 2.7% to 2.8 billion yuan.
A surge in licensing deals underscores China's rising innovation prowess. In 2025, Chinese drug makers sealed a record 157 out-licensing agreements valued at US$135.7 billion, doubling from 94 deals worth US$51.9 billion in 2024, per data from the National Medical Products Administration. These pacts grant exclusive rights for development, manufacturing, and commercialization in exchange for upfront payments, milestones, and royalties. Notable examples include Innovent Biologics' US$11.4 billion deal with Japan's Takeda for three cancer medicines, GeneQuantum's US$13 billion agreement with US-based Biohaven and South Korea's AimedBio for antibody-drug conjugates, 3SBio's US$6 billion pact with Pfizer for SSGJ-707, and Jiangsu Hengrui's US$12.5 billion collaboration with GlaxoSmithKline on HRS-9821 for chronic obstructive pulmonary disease.
Analysts attribute this depth of innovation to policy support and entrepreneurial momentum. Wang Jin from McKinsey observes that China's innovative drugs have improved in quality and quantity, backed by policies fostering supply chain innovation. Firms like Henlius provide a blueprint: starting with biosimilars and advancing to global innovators. Meng Tianying from Domo Medical consultancy emphasizes this path as representative of Chinese biotech's maturation.
Geopolitically, these developments align with Beijing's goal of technological self-reliance. As global tensions rise, bolstering core technologies in biotech fortifies China's position. The sector's growth not only drives economic expansion but also positions Chinese firms as true R&D partners on the world stage, moving beyond manufacturing to equity stakes and joint ventures. This shift promises sustained high growth, with overseas business displaying robust potential amid an integrated global framework.
Overall, China's pharma surge reflects intertwined factors: demographic pressures, innovation incentives, and strategic internationalization. Stakeholders in Asia's B2B life sciences ecosystem should monitor these trends closely, as they signal opportunities in partnerships, supply chains, and R&D collaborations across the region.
